Figure 4.
Antimyeloma activity of venetoclax in in vitro studies on human multiple myeloma cell lines (HMCLs). The HMCLs were treated with increasing concentrations of venetoclax for 24 and 48 h. Cell viability was assessed by 3‐(4,5‐dimethylthiazol‐2‐yl)−2,5‐diphenyltetrazolium bromide (MTT) assay. The means ± standard deviation of three independent experiments are represented.